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Aromatic dicationic compounds possess antimicrobial activity against a wide range of eucaryotic pathogens,
and in the present study an examination of the structures-functions of a series of compounds against fungi was
performed. Sixty-seven dicationic molecules were screened for their inhibitory and fungicidal activities against
Candida albicans and Cryptococcus neoformans. The MICs of a large number of compounds were comparable to
those of the standard antifungal drugs amphotericin B and fluconazole. Unlike fluconazole, potent inhibitory
compounds in this series were found to have excellent fungicidal activities. The MIC of one of the most potent
compounds against C. albicans was 0.39 mg/ml, and it was the most potent compound against C. neoformans
(MIC, <0.09 mg/ml). Selected compounds were also found to be active against Aspergillus fumigatus, Fusarium
solani, Candida species other than C. albicans, and fluconazole-resistant strains of C. albicans and C. neofor-
mans. Since some of these compounds have been safely given to animals, these classes of molecules have the
potential to be developed as antifungal agents.
The incidence of fungal infections in the immunocompro-
mised population has significantly increased over the past two
decades. Frequent infections caused by molds which may be
primarily resistant to azoles and azole-resistant isolates of Can-
dida albicans and Cryptococcus neoformans, which have devel-
oped recently, have increasingly been reported (7, 13, 23, 30).
In light of these developments, new antifungal agents with
various mechanisms of action and fungicidal activities are
needed for the effective management of these clinically impor-
tant infections.
Recently, we reported on the antifungal activities of ana-
logues and metabolites of pentamidine and a series of dicat-
ionic substituted bis-benzimidazoles (11). Those in vitro stud-
ies uncovered a number of compounds with potent activity
against C. albicans and C. neoformans. Several compounds
were found to have inhibitory activity against these two fungi
more potent than that of either fluconazole or amphotericin B.
In addition, the dicationic molecules, unlike fluconazole,
proved to have potent fungicidal activity, with the most potent
compounds having minimum fungicidal concentrations
(MFCs) below 1.0 mg/ml. These initial studies also found that
dicationic molecules were effective against Aspergillus fumiga-
tus, Fusarium solani, several Candida species other than C.
albicans, and fluconazole-resistant strains of C. albicans and C.
neoformans.
On the basis of the initial promising results reported above,
the current work expands our studies on the antifungal activ-
ities of dication-substituted molecules by screening 67 addi-
tional compounds against C. albicans and C. neoformans. The
criteria used to choose the structures for the current studies
were based on years of testing dicationic molecules against the
fungus Pneumocystis carinii in a rat model of disease (5, 14, 17,
18, 24, 26–28). Compounds in the current studies include mol-
ecules with the cationic moieties linked by carbazole, furan,
and benzimidazole bridges. In addition to screening all com-
pounds against C. albicans and C. neoformans, selected com-
pounds were tested against other yeasts, molds, and azole-
resistant strains of C. albicans and C. neoformans.
MATERIALS AND METHODS
Compounds. All compounds tested in this study were synthesized in the lab-
oratories of two of the authors (D.W.B. or R.R.T.). Stock solutions of 10,000
mg/ml were made in sterile distilled water or dimethyl sulfoxide (DMSO), as
recommended by the manufacturer, filter sterilized by passage through a 0.22-
mm-pore-size Millex Durapore membrane filter, and stored at 270°C until use.
The synthesis and physical properties for the following compounds have been or
will be described in the indicated publications: compounds 1 to 15 (22); com-
pounds 16 and 17 (10); compounds 18 (4); compounds 19 and 25 (29); com-
pounds 20 to 24 (6); compounds 29, 32, 39, 42, 45, and 47 (31); compounds 43,
44, and 46 (16); compounds 48 to 63 (9); and compounds 64 to 67 (25). The
remaining compounds (compounds 33 to 38, 40, and 41) have not been described
in previous publications, and brief descriptions of the synthesis and physical
properties of these novel compounds are given here, as follows.
Melting points (mp’s) were recorded with a Thomas Hoover (Uni-Melt) cap-
illary melting point apparatus or a Fisher-Johns apparatus and are uncorrected.
1H nuclear magnetic resonance (NMR) and 13C NMR spectra were recorded
with a Varian GX400 spectrometer, chemical shifts (d) are in parts per million
relative to tetramethylsilane, and coupling constants (J) are reported in hertz.
Mass spectra (MS) were recorded on a VG Instrument 70-SE spectrometer
(Georgia Institute of Technology, Atlanta). Infrared spectra were recorded with
a Michelson 100 instrument (Bomem, Inc.). Elemental analyses were performed
by Atlantic Microlab Inc. (Norcross, Ga.) and are within 60.4 of the theoretical
values. All chemicals and solvents were purchased from Aldrich Chemical Co. or
Fisher Scientific (4, 10).
General procedure for synthesis of compounds 33 to 37. To a suspension of
2,5-bis[4-carboxyphenyl]furan diacid chloride (6) (0.69 g, 0.002 mol) in 75 ml of
dry CH2Cl2 a substituted diamine (0.002 mol) was added, and the mixture was
stirred at room temperature for 6 h. The solvent was removed by distillation, the
residue was treated with ice water, the pH of the mixture was adjusted to 10 with
2 M NaOH, and the separated solid was filtered, washed with cold water, and
crystallized from ether-CHCl3 or ether-methanol to yield pale yellow solids in
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yields of 75 to 85%. The free base was converted to its HCl salt by treating the
free base with saturated ethanolic-HCl, with yields of 75 to 90%.
2,5-Bis-{4-[3-(N-morpholinopropyl)carbamoyl]phenyl}furan dihydrochloride
(compound 33). An 83% yield of a yellow crystalline solid (mp, 140 to 142°C
decompose [dec]) was obtained by the procedure described above. 1H NMR
(DMSO-d6/D2O): 7.93 (d, 4H, J 5 8.4 Hz), 7.86 (d, 4H, J 5 8.4 Hz), 7.15 (s, 2H),
3.86 (br m, 8H), 3.38 (br m, 12H), 3.16 (t, 4H, J 5 7.6 Hz), 2.0 (quintet, 4H, J 5
7.6 Hz). 13C NMR (DMSO-d6/D2O): 166.5, 152.7, 133.1, 132.4, 128.0, 123.4,
110.0, 63.3, 54.3, 51.3, 36.6, 23.4. MS m/e 560 (M1). Analysis calculated for
C32H40N4O5 z 2HCl: C, 60.65; H, 6.68; N, 8.84. Found: C, 60.59; H, 6.77; N, 8.87.
2,5-Bis[4-(2-N,N-dimethylaminoethylcarbamoyl)phenyl]furan dihydrochloride
(compound 34). An 80% yield of pale yellow crystalline solid (mp, 189 to 191°C
dec) was obtained by the procedure described above. 1H NMR (DMSO-d6/
D2O): 7.94 (d, 4H, J 5 8.4 Hz), 7.84 (d, 4H, J 5 8.4 Hz), 7.12 (s, 2H), 3.66 (t, 4H,
J 5 6.0 Hz), 3.30 (t, 4H, J 5 6.0 Hz), 2.84 (s, 12H). 13C NMR (DMSO-d6/D2O):
167.4, 152.9, 132.9, 132.7, 128.4, 123.7, 110.4, 56.6, 43.1, 34.9. MS m/e 448 (M1).
Analysis calculated for C26H32N4O3 z 2HCl: C, 59.88; H, 6.57; N, 10.74. Found:
C, 59.78; H, 6.66; N, 10.64.
2,5-Bis[4-(3-N,N-dimethylaminopropylcarbamoyl)phenyl]furan dihydrochlo-
ride (compound 35). A 75% yield of yellow hygroscopic solid (mp, 205 to 208°C
dec) was obtained by the procedure described above. 1H NMR (DMSO-d6):
10.91 (br, 2H), 8.80 (b s 2H), 8.03 (d, 4H, J 5 8.4 Hz), 7.92 (d, 4H, J 5 8.4 Hz),
7.23 (s, 2H), 3.40 (q, 4H, J 5 6 Hz), 3.15 (quintet, 4H, J 5 5.2 Hz), 2.76 (s, 6H),
2.75 (s, 6H), 2.02 (quintet, 4H, J 5 6.8 Hz). 13C NMR (DMSO-d6/D2O): 165.6,
152.4, 132.8, 131.9, 127.7, 122.9, 109.6, 54.3, 41.7, 36.2, 23.8. MS m/e 476 (M1).
Analysis calculated for C28H36N4O3 z 2HCl z 0.5 H2O: C, 60.21; H, 7.03; N, 10.03.
Found: C, 60.51; H, 7.13; N, 9.95.
2,5-Bis[4-(3-N-methyl-3-N-phenylaminopropylcarbamoyl)phenyl]furan dihy-
drochloride (compound 36). A 78% yield of yellow solid (mp, 85 to 88°C dec) was
obtained by the procedure described above. 1H NMR (DMSO-d6/D2O): 7.93 (d,
4H, J 5 8.4 Hz), 7.89 (d, 4H, J 5 8.4 Hz), 7.58 (d, 2H, J 5 8.8 Hz), 7.55 to 7.48
(m, 6H), 7.37 (S, 2H), 7.18 (s, 2H), 3.59 (m, 4H), 3.35 (t, 4H, J 5 7.2 Hz), 3.16
(s, 6H), 1.83 (quintet, 4H, J 5 7.2 Hz). 13C NMR (DMSO-d6/D2O): 166.4, 152.7,
133.1, 132.4, 130.1, 130.0, 128.0, 123.4, 119.7, 109.9, 55.3, 43.6, 36.5, 25.3. MS m/e
601 (M1). Analysis calculated for C38H40N4O3 z 2HCl z 0.75 H2O: C; 66.37; H,
6.34; N, 8.15. Found: C, 66.43; H, 6.34; N, 8.21.
2,5-Bis[4-(3-N,N8,N11-trimethylaminopropylcarbamoyl)phenyl]furan dihydro-
chloride (compound 37). An 85% yield of a yellow solid (mp, 245 to 247°C dec)
was obtained by the procedure described above. 1H NMR (DMSO-d6/D2O): 7.82
(d, 4H, J 5 8 Hz), 7.56 (d, 4H, J 5 8 Hz), 7.07 (s, 2H), 3.5 to 3.48 (m, 4H), 3.03
(brm, 4H), 2.94 (s, 6H), 2.76 (s, 12H), 1.98 (quintet, 4H, J 5 7.6 Hz). 13C NMR
(DMSO-d6/D2O): 171.2, 152.8, 135.4, 131.2, 127.9, 123.8, 109.7, 54.9, 42.7, 38.7,
22.4. MS m/e 504 (M1). Analysis calculated for C30H40N4O3 z 2HCl z 0.5 H2O:
C, 61.42; H, 7.38; N, 9.45. Found: C, 61.11; H, 7.27; N, 9.61.
2,5-Bis[3-amidinophenyl]furan dihydrochloride (compound 38). A suspen-
sion of the imidate ester dihydrochloride (0.87 g, 0.002 mol), prepared from
2,5-bis[3-cyanophenyl]furan (31), in 30 ml of absolute ethanol was saturated with
dry ammonia at 0 to 5°C, and the mixture was stirred at room temperature for
2 h. The solvent was removed; the solid was treated with ice water, filtered, and
basified with cold aqueous 2 M NaOH; and the off-white precipitate which
formed was filtered. The solid was washed with water and dried to yield 0.49 g
(80.6%; mp, 198 to 200°C). The free base (0.3 g, 0.001 mol) was converted into
the HCl salt by treating it with ethanolic HCl to yield 0.35 g (90%; mp 221 to
224°C dec). 1H NMR (DMSO-d6/D2O) 8.18 (br s, 2H), 8.10 (d, 2H, J 5 7.6 Hz),
7.68 (t, 2H, J 5 7.6 Hz), 7.64 (d, 2H, J 5 7.6 Hz), 7.14 (s, 2H). 13C NMR
(DMSO-d6): 166.1, 152.5, 131.3, 130.6, 129.3, 129.0, 127.4, 123.3, 110.5. MS (fast
atom bombardment [FAB]) m/e 305 (M1 1 1). Analysis calculated for
C18H16N4O z 2HCl z 0.25 H2O: C, 56.55; H, 4.88; N, 14.67. Found: C, 56.75; H,
4.84; N, 14.26.
2,5-Bis-[3-(N-isopropylamidino)amidinophenyl]furan dihydrochloride (com-
pound 40). The imidate ester hydrochloride (0.435 g, 0.001 mol), prepared from
2,5-bis(3-cyanophenyl)furan (31), and isopropyl amine (0.124 g, 0.0022 mol) in
10 ml of ethanol were stirred for 12 h and yielded, after standard workup, 0.13 g
(80%) of beige free base (mp, 180 to 181°C; crystallized from hexane-ether [3:1]).
On treatment with saturated ethanolic HCl, the free base yielded 0.29 g (75%)
of a crystalline solid (mp, 225 to 227°C dec). 1H NMR (DMSO-d6): 8.18 to 8.12
(m, 4H), 7.71 to 7.62 (m, 4H), 7.27 (s, 2H), 4.09 (quintet, 2H, J 5 6.4 Hz), 1.30
(d, 12H, J 5 6.4 Hz). 13C NMR (DMSO-d6): 161.6, 152.1, 130.4, 129.9, 129.7,
127.9, 127.3, 123.3, 110.1, 45.2, 21.2. MS (FAB) m/e 339 (M1 1 1). Analysis
calculated for C24H28N4O z 2HCl z 0.25 H2O: C, 61.86; H, 6.59; N, 12.02. Found:
C, 61.82; H, 6.27; N, 11.76.
TABLE 1. Structures and in vitro activities of dibenzocarbazoles
Compound X1a X2a Position X R
C. albicans C. neoformans
MIC (mg/ml) MFC (mg/ml) MIC (mg/ml) MFC (mg/ml)
Amphotericin B 1.0b NTc 1.0b NT
Fluconazole 0.25 NAd 2.0 NA
1 Am Am 3,6 H 25 25 12.5 25
2 Am Am 3,6 CH3 100 .100 25 50
3 Im Im 3,6 H .100 .100 3.12 25
4 IsopropAm IsopropAm 3,6 H .100 .100 .100 .100
5 Im Im 3,6 CH3 50 .100 1.56 1.56
6 Im Im 3,6 CHM 25 25 1.56 3.12
7 THP THP 3,6 CHM 100 .100 6.25 6.25
8 THP THP 3,6 CH3 .100 NT 25 50
9 BzIm BzIm 3,6 H 1.56 6.25 3.12 6.25
10 Am Am 2,7 H 0.78 1.56 6.25 50
11 Im Im 2,7 H 3.12 3.12 1.56 3.12
12 Im Im 2,7 CH3 12.5 50 1.56 3.12
13 BzIm BzIm 2,7 H 100 .100 25 50
14 Im OCH3 2,7 H .100 .100 .100 NT
15 Im OCH3 2,7 CH3 .100 .100 .100 NT
a
b 100% inhibition.
c NT, not tested.
d NA, no activity.
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2,5-Bis-3[(N-(2-dimethylaminoethyl)amidino]phenylfuran dihydrochloride
(compound 41). A mixture of imidate ester hydrochloride (0.435 g, 0.001 mol),
prepared from 2,5-bis[3-cyanophenyl]furan (31), and 2-dimethylaminoethyl-
amine (0.185 g, 0.0021 mol) in 10 ml of ethanol was stirred at room temperature
for 12 h. On standard workup 0.33 g (74%) of crystalline solid (mp, 75 to 77°C)
was obtained. On treatment with saturated ethanolic HCl, the free base (0.30 g,
0.00072 mol) gave 0.35 g (82%) hydrochloride salt (very hygroscopic), which was
dried at 75°C for 24 h (mp, 260 to 263°C dec). 1H NMR (DMSO-d6): 8.28
(brs,2H), 8.12 (d, 2H, J 5 8 Hz), 7.72 (d, 2H, J 5 8 Hz), 7.65 (t, 2H, J 5 8 Hz),
7.21 (s, 2H), 3.9 (t, 4H, J 5 4.2 Hz), 3.50 (t, 3H, J 5 4.2 Hz), 2.89 (s, 12H). 13C
NMR (DMSO-d6): 164.1, 152.4, 130.9, 130.3, 129.6, 128.8, 127.6, 123.7, 110.5,
54.5, 43.2, 38.4. MS (FAB) m/e 447 (M1 1 1). Analysis calculated for
C26H34N6O z 4HCl: C, 52.70; H, 6.46; N, 14.19. Found: C, 52.43; H, 6.42; N,
13.99.
Test organisms. The fungi tested included two quality control strains, C.
neoformans var. neoformans H99 and C. albicans A39, and the following clinical
isolates: four strains of C. neoformans var. neoformans (strains 167.95, 135.95,
114.96, and 133.95), of which three strains (strains 135.95, 114.96, and 133.95)
were fluconazole resistant (MICs, .64 mg/ml); two strains of C. neoformans var.
gattii (strains 119.95 and 114.95); two strains of fluconazole-resistant C. albicans
(MICs, .64 mg/ml; strains 102.96 and 103.96); and one strain each of Candida
parapsilosis (strain 111.96), Candida krusei (strain 132.91), Candida tropicalis
(strain 110.96), Candida lusitaniae (strain 111.92) Candida glabrata (strain
142.91), Rhizopus arrhizus (strain 117.89), Fusarium solani (strain 152.89), As-
pergillus fumigatus (strain 168.95), Aspergillus flavus (strain 112.96), and Paecilo-
myces lilacinus (strain 137.90).
Medium. Antifungal susceptibility testing was performed in RPMI 1640 me-
dium (Sigma, St. Louis, Mo.) with glutamine but without sodium bicarbonate and
buffered at pH 7.0 with 0.165 M morpholinopropanesulfonic acid.
In vitro susceptibility testing. Experiments for determination of MICs were
performed by the broth macrodilution method following the recommendations
of the National Committee for Clinical Laboratory Standards (21). The only
difference compared to the standardized method was the choice of drug dilu-
tions, which ranged from 100 to 0.09 mg/ml. Briefly, this method specifies the use
of an inoculum grown at 35°C and adjusted to a concentration of 0.5 3 103 to 2 3
103 CFU/ml, incubation at 35°C, and reading of the endpoints at 48 h for all
yeasts other than C. neoformans, for which the endpoints are read at 72 h. The
MIC was defined as the lowest drug concentration which produced a visual
turbidity indicating less than or equal to 80% inhibition compared with that in
the growth control tube.
Experiments for determination of MFCs were performed by a method adapted
from that of McGinnis (20). Briefly, 10-ml aliquots from tubes with growth
inhibition were plated onto Sabouraud agar plates. The lowest drug concentra-
tion that yielded three or fewer yeasts colonies was recorded as the MFC. Several
drugs were also rescreened by subculturing 100-ml aliquots from tubes with no
growth, and there was no change in the MFCs.
Molds were tested by the same method (21) but with the following modifica-
tions. Isolates were grown on Sabouraud dextrose agar at 30°C and were sub-
cultured twice to ensure viability. After adequate sporulation occurred (after 4 to
12 days), the conidia were harvested by flooding the colonies with a sterile
solution of 0.85% NaCl–0.05% Tween 80 in distilled water. Inoculum suspen-
sions were prepared by a hemocytometric procedure and were then diluted with
RPMI 1640 medium to obtain an inoculum size of approximately 0.5 3 103 to
2 3 103 CFU/ml. The inoculum size was verified by plating an aliquot of the
inoculum. The tubes were incubated at 30°C for 48 to 72 h or until growth in the
control tube was visible. The reproducibility of the method was quality controlled
by testing fluconazole and amphotericin B against C. albicans A39 and C. neo-
formans var. neoformans H99 in each experiment. The MICs of fluconazole for
C. albicans A39 and C. neoformans var. neoformans var. neoformans H99 were
0.25 and 2 mg/ml, respectively. The MIC of amphotericin B was 1 mg/ml for both
isolates.
RESULTS
Carbazoles. A series of 15 carbazoles (Table 1) were chosen
for antifungal screening on the basis of their high levels of
activity against P. carinii pneumonia (22). When the carbazoles
TABLE 2. Structures and in vitro activities of para-substituted symmetrical furans
Compound Y1 Y2a R1 R2
C. albicans C. neoformans
MIC (mg/ml) MFC (mg/ml) MIC (mg/ml) MFC (mg/ml)
Amphotericin B 1.0b NTc 1.0b NT
Fluconazole 0.25 NAd 2.0 NA
16 NH NH2 H H 6.25 25 12.5 25
17 NH NH2 CH3 CH3 6.25 6.25 3.12 3.12
18 NOCH3 NH2 H H .100 NT .100 NT
19 NH NH-cPr H H 25 25 3.12 50
20 NH NH-cBt H H 6.25 .50 0.78 6.25
21 NH NH-cPt H H 6.25 25 0.78 6.25
22 NH NH-cHx H H 12.5 12.5 1.56 6.25
23 NH NH-CH2-cPr H H 6.25 25 0.78 6.25
24 NH NH-CH2)2CH3 H H 12.5 12.5 1.56 6.25
25 NH NH-CH(CH3)2 H H 25 50 6.25 50
26 NH NH-CH(CH2CH3)2 H H 100 100 12.5 12.5
27 NH NH-CH2-CH(CH3)2 H H 12.5 NT 3.12 12.5
28 NH NH-(CH2)2-CH(CH3)2 H H 12.5 12.5 6.25 12.5
29 NH NH-(CH2)3-Pyr H H 100 NT 6.25 25
30 NH NH-(CH2)3PipCH3 H H .100 NT 12.5 50
31 NH NH-(CH2)4-NH(CH3)2 H H 12.5 25 #0.09 0.19
32 NH NH-(CH2)6-NH(CH3)2 H H .100 NT 1.56 3.12
33 ONH-(CH2)3Oxz H H .100 NT .100 NT
34 ONH-(CH2)2-NH(CH3)2 H H .100 NT .100 NT
35 ONH-(CH2)3-NH(CH3)2 H H .100 NT .100 NT
36 ONH-(CH2)3-NHCH3Ph H H .100 NT .100 NT
37 ONCH3-(CH2)3-NH(CH3)2 H H .100 NT .110 NT
a
b See footnote b of Table 1.
c NT, not tested.
d NA, no activity.
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were considered as a group, they appeared to have more po-
tent activity against C. neoformans than against C. albicans.
Examination of the data from Table 1 indicates that 2,7-sub-
stituted analogues (compounds 10, 11, and 12) were signifi-
cantly more effective than the corresponding 3,6-substituted
analogues (compounds 1, 3, and 5) against C. albicans. The
only exception to this observation was in the increased activity
of the 3,6-benzimidazole-substituted carbazole (compound 9)
TABLE 3. Structures and in vitro activities of meta-substituted symmetrical furansa
a See footnote b of Table 1 for explanation of amphotericin B MICs. Abbreviations: NT, not tested. NA, no activity.
TABLE 4. Structures and in vitro activities of asymmetrical furansa
a See footnote b of Table 1 for explanation of amphotericin B MICs. Abbreviations: NT, not tested. NA, no activity.
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compared to the activity of the corresponding 2,7-substituted
analogue (compound 13). In compounds 9 and 13 the distance
separating the cationic moieties is greatly increased, and these
compounds cannot be compared structurally with analogues
having the cationic groups attached directly to the carbazole
ring. The most potent carbazole against C. albicans was com-
pound 10, which had an MIC of 0.78 mg/ml and an MFC of 1.56
mg/ml. The MIC of this compound was in the same range as
that of fluconazole.
Several of the carbazole derivatives were found to have
activities against C. neoformans comparable to those of the
control drugs. The only dicationic carbazole devoid of activity
at 100 mg/ml against C. neoformans was the analogue with an
isopropyl group-substituted amidine (compound 4). The most
potent derivatives were compounds with imidazolines as the
cationic groups (compounds 3, 5, 6, 11, and 12). It is important
that replacement of one of the cationic moieties with a me-
thoxy group resulted in a significant reduction or loss of anti-
fungal activity against both organisms (compounds 14 and 15).
Furans. The series of compounds in which the cationic moi-
eties were substituted in the para position on a phenyl ring
attached to a 2,5-furanyl bridge (Table 2) was also selected for
testing against fungi on the basis of the excellent anti-pneu-
mocystis activities exhibited by selected members of the class
(5, 6). Several members of this series exhibited good activity
against C. albicans, but none of the compounds were found to
have activity equal to or better than that of amphotericin B or
fluconazole. Ten of the compounds in this series were devoid
of activity against C. albicans at the highest dose tested (100
mg/ml). This series exhibited greater potency against C. neo-
formans than against C. albicans, with the MICs of four of the
compounds (compounds 20, 21, 23, and 31) being lower than
the MICs of the control drugs. The MIC of the most potent
compound of the series (compound 31) against C. neoformans
was more than 10 times greater than that of amphotericin B
and 20 times greater than that of fluconazole. The only com-
pounds devoid of activity against C. neoformans were the com-
pounds with an amido moiety (compounds 33 to 37) and a
compound with methoxy group-substituted amidines (com-
pound 18).
The meta analogues of the compounds described above (Ta-
ble 3) exhibited only modest or no activity against C. albicans.
A significant increase in activity is noted for the para-substi-
tuted compounds over the meta-substituted analogues (com-
pare compounds 16 and 38 and compounds 25 and 40). The
meta analogues are more potent against C. neoformans than
against C. albicans. Against C. neoformans the meta analogues
were as potent or slightly more potent than their para coun-
terparts.
Like the compounds described above, those in Table 4 have
the furan ring in the bridge between the cation-containing
rings. However, these compounds are asymmetrical and have
TABLE 5. Structures and in vitro activities of benzimidazoles
Compound Ya Ra
C. albicans C. neoformans
MIC (mg/ml) MFC (mg/ml) MIC (mg/ml) MFC (mg/ml)
Amphotericin B 1.0b NTc 1.0b NT
Fluconazole 0.25 NAd 2.0 NA
48 BzIm OH 3.12 NT 3.12 NT
49 BzIm OCH3 0.78 NT 3.12 3.12
50 BzIm OC2H5 0.78 12.5 1.56 1.56
51 BzTHP OH 3.12 25 1.56 6.25
52 BzAm OH 0.78 6.25 3.12 6.25
53 BzAm Am 0.39 1.56 #0.09 0.78
54 BzIm Im 0.78 1.56 0.39 0.39
55 BzAm OCH3 .100 NT 3.12 .25
56 BzTHP THP 0.78 1.56 0.19 0.39
57 BzAm OC2H5 0.78 1.56 1.56 1.56
58 BzMPZ OH 25 50 100 .100
59 Im OCH3 25 NT 50 100
60 Am Am 100 .100 25 50
61 Am OH .100 NT .100 .100
62 Im Im 50 .100 50 NT
63 THP THP 50 100 25 50
64 Am O(CH2)3OPhAm 0.39 0.78 0.19 0.78
65 Am O(CH2)4OPhAm 0.39 3.12 #0.09 1.56
66 Am O(CH2)5OPhAm 0.78 1.56 0.39 6.25
67 Am OPhAm 0.78 0.78 0.78 6.25
a
b See footnote b of Table 1.
c NT, not tested.
d NA, no activity.
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one cation on a benzimidazole ring, while the second cation is
attached to a phenyl ring. Only two of these compounds (com-
pound 43 and 45) exhibited significant activity against C. albi-
cans. All five of the compounds of this series had good activity
against C. neoformans. The two most potent compounds
against C. neoformans (compounds 43 and 45) were the only
two structures showing significant activity against C. albicans.
Benzimidazoles. The compounds depicted in Table 5 are all
characterized by having a 2-phenylbenzimidazole as the central
linker between the cationic moieties. Molecules in this group
have previously been studied for their DNA minor groove
binding (8, 9) and protease inhibition (25) properties. Because
we have associated the ability of these molecules to bind in the
minor groove of DNA with their antimicrobial activity (1, 24),
compounds 48 to 63 were logical choices for antifungal testing.
In addition to being studied for antitrypsin potency, com-
pounds 64 to 67 were determined to be excellent DNA binding
agents and to have potent anti-P. carinii activities (23a). Eleven
of the compounds in this series were found to have activity
against C. albicans approaching the same level as those of
amphotericin B and fluconazole. The MICs of three of the
compounds (compounds 53, 64, and 65) for C. albicans were
0.39 mg/ml. Ten of the compounds in this group had potencies
equal to or greater than those of the control drugs against C.
neoformans, with two compounds (compounds 53 and 65) ex-
hibiting a 10-fold greater potency than amphotericin B. In
addition, seven compounds (compounds 53, 54, 56, and 64 to
67) demonstrated excellent activity against both fungi com-
pared to the activities of amphotericin B and fluconazole.
Broad-spectrum activities of compounds 10, 21, and 53.
Three compounds were selected for extended in vitro suscep-
tibility testing to determine their spectra of antifungal activity.
Compound 10 was chosen as an example of the carbazole
group on the basis of the excellent activity of the compound
against P. carinii (22) and Cryptosporidium parvum (3) and the
low level of toxicity of the compound in rats (22). Compound
21 was chosen on the basis of its good in vitro activity against
C. albicans and C. neoformans and the availability of the com-
pound. Compound 53 was chosen from the benzimidazole
group because of its excellent activity against C. albicans and C.
neoformans. The compounds were tested against Candida
strains other than C. albicans including fluconazole-resistant
isolates, several C. neoformans isolates including serotype B
and C isolates, and some clinically important molds. All three
compounds exhibited broad-spectrum activity (Table 6). Com-
pound 10 was active against all strains of Candida and Crypto-
coccus tested, with excellent potency against C. tropicalis. Com-
pound 10 showed good activity against A. fumigatus but only
modest activity against A. flavus, F. solani, P. lilacinus, and R.
arrhizus. Compound 21 showed a pattern of activity very sim-
ilar to that of compound 10. A notable difference between the
two compounds was that compound 10 tended to be more
effective against Candida strains, while compound 21 exhibited
more potency toward Cryptococcus strains. Compound 21 was
observed to be active against fluconazole-resistant strains of C.
albicans. Compound 53 showed excellent activity against all
strains tested with the exceptions of A. flavus, P. lilacinus, and
R. arrhizus. This compound was highly potent against A. fu-
migatus and F. solani and all strains of Cryptococcus and Can-
dida.
DISCUSSION
The antifungal data from Tables 1 to 5 indicate that a num-
ber of the 67 compounds tested exhibit activities equal to or
greater than those of fluconazole and amphotericin B. As we
reported earlier (11), this class of compounds is not only in-
hibitory but also shows in vitro fungicidal activity.
In addition to the activities of the compounds against several
isolates of C. neoformans and C. albicans, it was encouraging to
TABLE 6. Extended antifungal spectra of selected compounds
Strain
Compound 10 Compound 21 Compound 53
MIC (mg/ml) MFC (mg/ml) MIC (mg/ml) MFC (mg/ml) MIC (mg/ml) MFC (mg/ml)
C. albicans A39 0.78 1.56 6.25 25 0.39 1.56
C. albicans 102.96a NTb NT 12.5 12.5 NT NT
C. albicans 103.96a NT NT 12.5 12.5 NT NT
C. krusei 132.91 1.56 12.5 12.5 .100 0.39 0.39
C. lusitaniae 111.92 3.12 25 6.25 25 0.39 1.56
C. parapsilosis 111.96 0.78 .6.25 6.25 100 0.39 0.39
C. tropicalis 110.96 #0.09 0.19 3.12 12.5 0.39 0.39
C. glabrata 142.91 0.78 .12.5 0.78 .6.25 #0.09 0.78
C. neoformans H99 6.25 .50 0.39 6.25 #0.09 0.78
C. neoformans 114.95c 6.25 12.5 0.78 3.12 0.19 0.39
C. neoformans 119.95d 1.56 6.25 0.39 1.56 0.19 0.39
C. neoformans 133.95a NT NT 0.39 1.56 NT NT
C. neoformans 135.95a 3.12 6.25 0.39 1.56 #0.09 0.19
C. neoformans 167.95 NT NT 0.39 0.78 NT NT
C. neoformans 114.96a 6.25 25 0.78 1.56 #0.09 0.19
A. flavus 112.96 50 50 25 NT .100 NT
A. fumigatus 168.95 3.12 25 1.56 NT #0.09 NT
F. solani 152.89 50 100 .100 NT 0.19 NT
P. lilacinus 137.90 100 NT .100 NT .100 NT
R. arrhizus 117.89 25 50 25 NT .100 NT
a Fluconazole-resistant isolates.
b NT, Not tested.
c Serotype B.
d Serotype C.
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find that selected molecules exhibited activity against other
yeasts and molds. Particularly exciting was compound 53,
which was found to have excellent activity against C. albicans,
C. neoformans, A. fumigatus, and F. solani.
Comparison of the reported DNA binding data for these
compounds (5, 6, 8, 22) with the corresponding antifungal
activity reveals no direct correlation between affinity for the
minor groove of DNA and their antifungal activities. However,
the only compounds in this series that did not bind in the minor
groove of DNA (compounds 14 and 15) (22) were also devoid
of antifungal activity at the highest dose tested, 100 mg/ml.
These data are supportive of our hypothesis that minimal DNA
binding is necessary for, but not an assurance of, antimicrobial
activity (22). We have theorized that the binding of compounds
to the DNA results in competitive inhibition of key DNA-
directed enzymes. Therefore, the strength of DNA binding is
not as important as the site of binding in the minor groove (2,
11, 22). Previously, we had reported that there was a strong
correlation between the antigiardial activity of dicationic mol-
ecules and their ability to bind in the minor groove and to
inhibit topoisomerase II (2). Our present data suggest that
topoisomerase I is probably not the target of these compounds
in C. neoformans, as for camptothecin and its congeners (12).
It has been hypothesized that the primary cellular target of a
dicationic compound, pentamidine, in S. cerevisiae is the mito-
chondrion (19), and more recently, it has been suggested that
these compounds have an effect on P. carinii due to DNA
binding followed by inhibition of an endo- or exonuclease (15).
A key to the further development of these dicationic molecules
as antifungal agents will be to establish their mechanisms of
action. The ability to readily grow these fungi in vitro com-
pared to the ability to grow giardia, cryptosporidium, and
pneumocystis in vitro bodes well for future studies into deter-
mining the mechanism(s) of antifungal activity of these dicat-
ionic molecules.
In addition to determining the mechanisms of action of
dicationic molecules and developing a rational approach to
drug design, lead compounds (i.e., compound 53) will be re-
synthesized for testing in animal models of fungal disease. If it
can be determined that dicationic molecules are effective in
vivo, the enthusiasm for this class of compounds as clinically
useful antifungal agents will be greatly increased.
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